European Pharmaceutical Review

JUNE 28, 2022

billion by 2026, achieving a compound annual growth rate (CAGR) of 13.2 percent CAGR between 2022 and 2026. The Asia-Pacific market is expected to grow the most in years to come, as people’s income rises, healthcare expenditure grows and the population expands. YMC Europe GmbH.

Marketing 111

Marketing Government Healthcare Healthcare 111

pharmaphorum

JANUARY 29, 2023

With the population ageing, the need for healthcare is growing fast: between 2015 and 2050, the proportion of the world’s population over 60 years old will nearly double from 12% to 22%, according to the World Health Organization. Secondly, pressure on healthcare spending is leading to greater consolidation.

Healthcare 91

Healthcare Healthcare Manufacturing Marketing 91

Clarivate

OCTOBER 31, 2023

These years witnessed significant troughs in pharma financing, a drop in the capital markets, and an IPO window that remained firmly shut. Big pharma is still keen to access good technology, science, and assets, in many cases to plug a patent-expiry-shaped hole in their coffers. In short, the biotech bubble had burst. Pfizer’s $11.6

Pharma 52

Pharma Biopharma Marketing Healthcare 52

PM360

SEPTEMBER 28, 2022

By 2026, the U.S. The consequences for the health industry are huge—especially considering the Hispanic population is traditionally considered a “healthcare powerhouse.” Roughly 62% prefer healthcare information resources in Spanish, while 67% say their cultural heritage influences their purchase decisions. Census estimates 69.7

Patients 98

Patients Marketing Doctors Healthcare 98

PM360

SEPTEMBER 21, 2023

The product, manufactured by ARS Pharma and Neurelis Pharma, would be the first needle-free epinephrine alternative to autoinjectors, such as the EpiPen. Starting in 2026, the provision will affect 10 Part D drugs. Casberg said his company is getting many queries from payers and PBMs about these issues.

Management 105

Management Manufacturing Sales Competition 105

PM360

APRIL 7, 2023

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Most immediately, it will add confusion in the healthcare space,” explains Daniel Sontupe, Associate Partner, Managing Director, The Bloc Value Builders.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

pharmaphorum

JANUARY 18, 2023

German pharma group Bayer has made another play in the digital medical imaging category, buying Blackford Analysis and its artificial intelligence-based platform for radiological assessments. billion) in 2021, around 10% of the group’s total healthcare revenues. The business generated sales of €1.8 billion (approximately $1.9

Medical 59

Medical Pharma Media Sales 59

pharmaphorum

JULY 26, 2022

NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging with black cheque company Frazier Lifesciences in a deal that will provide additional cash for its main drug candidate – oral CETP inhibitor obicetrapib. Remember CETP? Amgen licensed the rights to NewAmsterdam in 2020.

Side effects 52

Side effects Safety Pharma Patients 52

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

PM360

SEPTEMBER 21, 2023

As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. 1 We have been improving patient affordability for over a decade, across generic and brand medications, including specialty treatments—sometimes by more than 50%.

Prescription 52

Prescription Medical Patients Distribution 52

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. Pharma simply has less interactive time with doctors. Launch opportunity is reduced. That impacts launches most.

Doctors 59

Doctors Medicine Marketing Sales 59

Pharmaceutical Technology

JANUARY 31, 2023

FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San Francisco over January 9–12. That leaves three years for pharma companies to prepare.

FDA 52

FDA Prescription Medicine Biopharma 52

PM360

FEBRUARY 1, 2024

Confidence Amidst Funding Challenges The resilience and confidence observed amidst funding challenges within the biotech sector represent a testament to the industry’s steadfast commitment to innovation and transformative advancements in healthcare.

Recruitment 52

Recruitment Healthcare Healthcare Management 52

European Pharmaceutical Review

AUGUST 19, 2022

billion by 2026. In addition, investigators cited the increasing geriatric patient population, growing consumption of medicines, rising healthcare expenditure, improving healthcare infrastructure in emerging markets and mounting pressure to reduce healthcare costs as other factors driving market growth. Within the $130.2

Manufacturing 98

Manufacturing Marketing Pharma Healthcare 98

pharmaphorum

DECEMBER 14, 2022

As many strive to bring about transformation in healthcare, Angelini Ventures takes a new approach to investments in digital health and life sciences companies that drive healthcare innovation and improve patient experiences. It aims to shape companies in the digital healthcare, connected medical devices, and life sciences spaces.

Healthcare 105

Healthcare Healthcare Patients Management 105

Pharmaceutical Technology

JANUARY 16, 2023

Pharma may have to navigate a difficult path through relatively slow-to-fall inflation in regions outside the US. Negotiated prices will not apply until 2026, but the selected medicines for Medicare price negotiations will be unveiled in September 2023. The entire pharma industry will be affected by the fallout. Free Report.

Pharma 64

Pharma Pharmaceutical Manufacturing Marketing 64

Pharmaceutical Technology

JANUARY 16, 2023

Pharma may have to navigate a difficult path through relatively slow-to-fall inflation in regions outside the US. Negotiated prices will not apply until 2026, but the selected medicines for Medicare price negotiations will be unveiled in September 2023. The entire pharma industry will be affected by the fallout. Free Report.

Pharma 52

Pharma Pharmaceutical Manufacturing Marketing 52

Clarivate

AUGUST 20, 2024

Price negotiations will be staggered over time, beginning with this initial list of ten Part D drugs that takes effect in 2026 (Part D is the prescription drug coverage component of Medicare, a federal health insurance program for people 65 and older which covers nearly 1 in 5 Americans). These ten drugs cost Medicare Part D nearly $46.8

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

World of DTC Marketing

JULY 28, 2022

Still, the pharma industry is fighting hard to keep it off the table. Late last year, the Senate Finance Committee released draft legislation enabling Medicare negotiation for up to 10 drugs in 2025, 15 in 2026 and 2027, and 20 in 2028 and beyond. Pharma is a very profitable industry. The secretary of the U.S.

Pharma 256

Pharma Prescription Pharmaceutical Manufacturing 256

Clarivate

OCTOBER 17, 2024

Healthcare delivery has not been the hottest topic on the campaign trail this election season, despite sharp policy differences between the candidates and parties. These prior actions align with the Biden Administration’s policy of strict antitrust enforcement, particularly concerning healthcare. During the Sept.

Healthcare 52

Healthcare Healthcare Government Insurance 52